Figures & data
Figure 1 Effect of DLBS1442 on angiogenesis-regulating factors and cell migration.
Abbreviations: C, control; DMSO, dimethyl sulfoxide; HIF-1α, hypoxia-inducible factor-1α; MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor.
![Figure 1 Effect of DLBS1442 on angiogenesis-regulating factors and cell migration.](/cms/asset/ed1d25f1-c946-4569-849a-4ccf6648e312/djwh_a_74552_f0001_c.jpg)
Figure 2 Expression of ERβ and PR-B in DLBS1442-treated RL95-2 cells.
Abbreviations: C, control; ERβ, estrogen receptor beta; PR-B, progesterone receptor B.
![Figure 2 Expression of ERβ and PR-B in DLBS1442-treated RL95-2 cells.](/cms/asset/1f086173-a097-4e69-b682-d463c7e740cc/djwh_a_74552_f0002_b.jpg)
Figure 3 DLBS1442 works via eicosanoid pathway.
Abbreviations: COX-2, cyclooxygenase-2; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; iNOS, inducible nitric oxide synthase; NFκβ, nuclear factor kappa β; cPLA2, cytosolic phospholipase A2.
![Figure 3 DLBS1442 works via eicosanoid pathway.](/cms/asset/82bf015c-a19f-4dd6-b39c-25c8a2b82d35/djwh_a_74552_f0003_b.jpg)
Figure 4 DLBS1442 inhibits RL95-2 cell viability and induces cellular apoptosis.
![Figure 4 DLBS1442 inhibits RL95-2 cell viability and induces cellular apoptosis.](/cms/asset/4033ae91-bea8-4954-8382-6ac68248e5cc/djwh_a_74552_f0004_b.jpg)